Loss of Pentameric Symmetry of C-reactive Protein is Associated with Promotion of Neutrophil-endothelial Cell Adhesion
Overview
Authors
Affiliations
The classic acute-phase reactant C-reactive protein (CRP) is a cyclic pentameric protein that diminishes neutrophil accumulation in inflamed tissues. When the pentamer is dissociated, CRP subunits undergo conformational rearrangement that results in expression of a distinctive isomer with unique antigenic and physicochemical characteristics (termed modified CRP (mCRP)). Recently, mCRP was detected in the wall of normal human blood vessels. We studied the impact and mechanisms of action of mCRP on expression of adhesion molecules on human neutrophils and their adhesion to human coronary artery endothelial cells. Both CRP and mCRP (0.1-200 microg/ml) down-regulated neutrophil L-selectin expression in a concentration-dependent fashion. Furthermore, mCRP, but not CRP, up-regulated CD11b/CD18 expression and stimulated neutrophil extracellular signal-regulated kinase activity, which was accompanied by activation of p21(ras) oncoprotein, Raf-1, and mitogen-activated protein kinase kinase. These actions of mCRP were sensitive to the mitogen-activated protein kinase kinase inhibitor PD98059. mCRP markedly enhanced attachment of neutrophils to LPS-activated human coronary artery endothelial when added together with neutrophils. This effect of mCRP was attenuated by an anti-CD18 mAb. Thus, loss of pentameric symmetry in CRP is associated with appearance of novel bioactivities in mCRP that enhance neutrophil localization and activation at inflamed or injured vascular sites.
Higher monomeric C-reactive protein levels are associated with premature coronary artery disease.
Melnikov I, Kozlov S, Okhota S, Saburova O, Avtaeva Y, Kuznetsova T Front Immunol. 2025; 15:1501125.
PMID: 39867895 PMC: 11757105. DOI: 10.3389/fimmu.2024.1501125.
Cytokine Storm among Bangladeshi adults with COVID-19: A prospective cohort study.
Sarmin M, Akter F, Islam A, Mahfuz M, Das S, Sharifuzzaman Heliyon. 2024; 10(23):e40532.
PMID: 39654713 PMC: 11625268. DOI: 10.1016/j.heliyon.2024.e40532.
Olson M, Hornick M, Stefanski A, Albanna H, Gjoni A, Hall G Front Immunol. 2023; 14:1264383.
PMID: 37781355 PMC: 10540681. DOI: 10.3389/fimmu.2023.1264383.
C-reactive protein: a target for therapy to reduce inflammation.
Rizo-Tellez S, Sekheri M, Filep J Front Immunol. 2023; 14:1237729.
PMID: 37564640 PMC: 10410079. DOI: 10.3389/fimmu.2023.1237729.
Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives.
Melnikov I, Kozlov S, Saburova O, Avtaeva Y, Guria K, Gabbasov Z Int J Mol Sci. 2023; 24(3).
PMID: 36768404 PMC: 9917083. DOI: 10.3390/ijms24032079.